A Phase I Study of SY-4835 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-07-28
Target enrollment:
Participant gender:
Summary
This is a phase 1, open-label, single-arm, first-in-human study to evaluate the safety,
tolerability, pharmacokinetics (PK) and anti-tumor activity of SY-4835 administered orally in
patients with advanced solid tumors.